Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Swiss pharmaceutical giant Novartis (NYSE:NVS) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Novartis and see what CAPS investors are saying about the stock right now.

Novartis facts

 

 

Headquarters (founded)

Basel, Switzerland (1895)

Market Cap

$179.7 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$57.8 billion

Management

CEO Joseph Jimenez

CFO Harry Kirsch

Return on Equity (average, past 3 years)

14.9%

Cash/Debt

$6.0 billion/$20.9 billion

Dividend Yield

3.4%

Competitors

Merck 

Pfizer 

Sanofi 

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 1,512 members who have rated Novartis believe the stock will outperform the S&P 500 going forward.   

Just yesterday, one of those Fools, TMFTailwind, succinctly summed up the Novartis bull case for our community:

[Novartis] has an enviable strategic position with a nice pipeline of late-stage products. Diversified product lines buffer the company from difficulties in any one segment. [Novartis] also benefits from increased adoption of generic drugs. Steady, defensive big pharma play with a good margin of safety at current levels.

Fool contributor Brian Pacampara and The Motley Fool have no position in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.